Alerts
COVID-19 update
See our updated visitor policy, which now allows 1 visitor per patient during exams only. No visitors are allowed in treatment (applies at all locations). Only exceptions are patients with physical or mental disability.
Skip Navigation

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations

Brief Summary

Type:
Multiple Sites (Solid Tumors)

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT04284774

Study #:
CMH - APEC1621M

Start Date:
Jul 19, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04284774

View Complete Trial Details & Eligibility at ClinicalTrials.gov